130 related articles for article (PubMed ID: 35393528)
1. Augmented FLAMSA-Bu versus FluBu2 reduced-intensity conditioning in patients with active relapsed/refractory acute myeloid leukemia: an EBMT analysis.
Rodríguez-Arbolí E; Labopin M; Eder M; Brecht A; Blau IW; Huynh A; Forcade E; Tischer J; Bethge W; Bondarenko S; Verbeek M; Bulabois CE; Einsele H; Stölzel F; Savani B; Spyridonidis A; Bazarbachi A; Giebel S; Brissot E; Schmid C; Nagler A; Mohty M
Bone Marrow Transplant; 2022 Jun; 57(6):934-941. PubMed ID: 35393528
[TBL] [Abstract][Full Text] [Related]
2. FLAMSA-Based Reduced-Intensity Conditioning versus Myeloablative Conditioning in Younger Patients with Relapsed/Refractory Acute Myeloid Leukemia with Active Disease at the Time of Allogeneic Stem Cell Transplantation: An Analysis from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation.
Rodríguez-Arbolí E; Labopin M; Tischer J; Brecht A; Ganser A; Finke J; Blau IW; Kröger N; Kalhs P; Forcade E; Bunjes D; Spyridonidis A; Savani B; Nagler A; Mohty M
Biol Blood Marrow Transplant; 2020 Nov; 26(11):2165-2173. PubMed ID: 32717436
[TBL] [Abstract][Full Text] [Related]
3. Fludarabine-treosulfan compared to thiotepa-busulfan-fludarabine or FLAMSA as conditioning regimen for patients with primary refractory or relapsed acute myeloid leukemia: a study from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation (EBMT).
Saraceni F; Labopin M; Brecht A; Kröger N; Eder M; Tischer J; Labussière-Wallet H; Einsele H; Beelen D; Bunjes D; Niederwieser D; Bochtler T; Savani BN; Mohty M; Nagler A
J Hematol Oncol; 2019 Apr; 12(1):44. PubMed ID: 31023346
[TBL] [Abstract][Full Text] [Related]
4. Reduced Relapse Incidence with FLAMSA-RIC Compared with Busulfan/Fludarabine for Acute Myelogenous Leukemia Patients in First or Second Complete Remission: A Study from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation.
Heinicke T; Labopin M; Schmid C; Polge E; Socié G; Blaise D; Mufti GJ; Huynh A; Brecht A; Ledoux MP; Cahn JY; Milpied N; Scheid C; Hicheri Y; Mohty M; Savani BN; Nagler A
Biol Blood Marrow Transplant; 2018 Nov; 24(11):2224-2232. PubMed ID: 30009981
[TBL] [Abstract][Full Text] [Related]
5. Comparison of FLAMSA-based reduced intensity conditioning with treosulfan/fludarabine conditioning for patients with acute myeloid leukemia: an ALWP/EBMT analysis.
Sheth V; Labopin M; Canaani J; Volin L; Brecht A; Ganser A; Mayer J; Labussière-Wallet H; Bittenbring J; Shouval R; Savani B; Mohty M; Nagler A
Bone Marrow Transplant; 2019 Apr; 54(4):531-539. PubMed ID: 30087463
[TBL] [Abstract][Full Text] [Related]
6. Conditioning with fludarabine and treosulfan compared to FLAMSA-RIC in allogeneic stem cell transplantation for myeloid malignancies: a retrospective single-center analysis.
Braitsch K; Schwarz A; Koch K; Hubbuch M; Menzel H; Keller U; Götze KS; Bassermann F; Herhaus P; Verbeek M
Ann Hematol; 2022 Jun; 101(6):1311-1319. PubMed ID: 35364726
[TBL] [Abstract][Full Text] [Related]
7. Risk factors for outcome in refractory acute myeloid leukemia patients treated with a combination of fludarabine, cytarabine, and amsacrine followed by a reduced-intensity conditioning and allogeneic stem cell transplantation.
Pfrepper C; Klink A; Behre G; Schenk T; Franke GN; Jentzsch M; Schwind S; Al-Ali HK; Hochhaus A; Niederwieser D; Sayer HG
J Cancer Res Clin Oncol; 2016 Jan; 142(1):317-24. PubMed ID: 26424692
[TBL] [Abstract][Full Text] [Related]
8. Impact on Outcome of Minimal Residual Disease after Hematopoietic Stem Cell Transplantation with Fludarabine, Amsacrine, and Cytosine Arabinoside-Busulfan Conditioning: A Retrospective Monocentric Study.
Meur GL; Plesa A; Larcher MV; Fossard G; Barraco F; Loron S; Balsat M; Ducastelle-Leprêtre S; Gilis L; Thomas X; Ghesquières H; Tigaud I; Hayette S; Huet S; Sujobert P; Renault M; Thérèse RM; Michallet M; Labussière-Wallet H; Heiblig M
Transplant Cell Ther; 2023 Jan; 29(1):38.e1-38.e9. PubMed ID: 36108977
[TBL] [Abstract][Full Text] [Related]
9. Busulfan dose intensity and outcomes in reduced-intensity allogeneic peripheral blood stem cell transplantation for myelodysplastic syndrome or acute myeloid leukemia.
Chen YB; Coughlin E; Kennedy KF; Alyea EP; Armand P; Attar EC; Ballen KK; Cutler C; Dey BR; Koreth J; McAfee SL; Spitzer TR; Antin JH; Soiffer RJ; Ho VT
Biol Blood Marrow Transplant; 2013 Jun; 19(6):981-7. PubMed ID: 23562738
[TBL] [Abstract][Full Text] [Related]
10. Comparison of myeloablative and reduced intensity conditioning unrelated donor allogeneic peripheral blood stem cell transplant outcomes for AML using thymoglobulin for GVHD prophylaxis.
Modi D; Singh V; Kim S; Ayash L; Deol A; Ratanatharathorn V; Uberti JP
Ann Hematol; 2021 Apr; 100(4):969-978. PubMed ID: 33594448
[TBL] [Abstract][Full Text] [Related]
11. Augmented Reduced-Intensity Regimen Does Not Improve Postallogeneic Transplant Outcomes in Acute Myeloid Leukemia.
Craddock C; Jackson A; Loke J; Siddique S; Hodgkinson A; Mason J; Andrew G; Nagra S; Malladi R; Peniket A; Gilleece M; Salim R; Tholouli E; Potter V; Crawley C; Wheatley K; Protheroe R; Vyas P; Hunter A; Parker A; Wilson K; Pavlu J; Byrne J; Dillon R; Khan N; McCarthy N; Freeman SD
J Clin Oncol; 2021 Mar; 39(7):768-778. PubMed ID: 33373276
[TBL] [Abstract][Full Text] [Related]
12. Similar outcome after allogeneic stem cell transplantation with a modified FLAMSA conditioning protocol substituting 4 Gy TBI with treosulfan in an elderly population with high-risk AML.
Holtick U; Herling M; Pflug N; Chakupurakal G; Leitzke S; Wolf D; Hallek M; Scheid C; Chemnitz JM
Ann Hematol; 2017 Mar; 96(3):479-487. PubMed ID: 27909887
[TBL] [Abstract][Full Text] [Related]
13. Fludarabine and Busulfan versus Fludarabine, Cyclophosphamide, and Rituximab as Reduced-Intensity Conditioning for Allogeneic Transplantation in Follicular Lymphoma.
Epperla N; Ahn KW; Armand P; Jaglowski S; Ahmed S; Kenkre VP; Savani B; Jagasia M; Shah NN; Fenske TS; Sureda A; Smith SM; Hamadani M
Biol Blood Marrow Transplant; 2018 Jan; 24(1):78-85. PubMed ID: 29032272
[TBL] [Abstract][Full Text] [Related]
14. Combination of fludarabine, amsacrine, and cytarabine followed by reduced-intensity conditioning and allogeneic hematopoietic stem cell transplantation in patients with high-risk acute myeloid leukemia.
Krejci M; Doubek M; Dusek J; Brychtova Y; Racil Z; Navratil M; Tomiska M; Horky O; Pospisilova S; Mayer J
Ann Hematol; 2013 Oct; 92(10):1397-403. PubMed ID: 23728608
[TBL] [Abstract][Full Text] [Related]
15. Impact of in vivo T cell depletion in HLA-identical allogeneic stem cell transplantation for acute myeloid leukemia in first complete remission conditioned with a fludarabine iv-busulfan myeloablative regimen: a report from the EBMT Acute Leukemia Working Party.
Rubio MT; D'Aveni-Piney M; Labopin M; Hamladji RM; Sanz MA; Blaise D; Ozdogu H; Daguindeau E; Richard C; Santarone S; Irrera G; Yakoub-Agha I; Yeshurun M; Diez-Martin JL; Mohty M; Savani BN; Nagler A
J Hematol Oncol; 2017 Jan; 10(1):31. PubMed ID: 28118857
[TBL] [Abstract][Full Text] [Related]
16. Reduced-Intensity Conditioning with Busulfan, Fludarabine, and Antithymocyte Globulin for Hematopoietic Cell Transplantation from Unrelated or Haploidentical Family Donors in Patients with Acute Myeloid Leukemia in Remission.
Lee KH; Lee JH; Lee JH; Kim DY; Park HS; Choi EJ; Ko SH; Seol M; Lee YS; Kang YA; Jeon M; Baek S; Kang YL; Kim SH; Yun SC; Kim H; Jo JC; Choi Y; Joo YD; Lim SN
Biol Blood Marrow Transplant; 2017 Sep; 23(9):1555-1566. PubMed ID: 28552421
[TBL] [Abstract][Full Text] [Related]
17. Reduced-intensity conditioning with fludarabine and busulfan versus fludarabine and melphalan for patients with acute myeloid leukemia: a report from the Acute Leukemia Working Party of the European Group for Blood and Marrow Transplantation.
Baron F; Labopin M; Peniket A; Jindra P; Afanasyev B; Sanz MA; Deconinck E; Nagler A; Mohty M
Cancer; 2015 Apr; 121(7):1048-55. PubMed ID: 25424330
[TBL] [Abstract][Full Text] [Related]
18. Allogeneic hematopoietic stem-cell transplantation for acute myeloid leukemia in remission: comparison of intravenous busulfan plus cyclophosphamide (Cy) versus total-body irradiation plus Cy as conditioning regimen--a report from the acute leukemia working party of the European group for blood and marrow transplantation.
Nagler A; Rocha V; Labopin M; Unal A; Ben Othman T; Campos A; Volin L; Poire X; Aljurf M; Masszi T; Socie G; Sengelov H; Michallet M; Passweg J; Veelken H; Yakoub-Agha I; Shimoni A; Mohty M
J Clin Oncol; 2013 Oct; 31(28):3549-56. PubMed ID: 23980086
[TBL] [Abstract][Full Text] [Related]
19. Comparative effectiveness of busulfan/cyclophosphamide versus busulfan/fludarabine myeloablative conditioning for allogeneic hematopoietic cell transplantation in acute myeloid leukemia and myelodysplastic syndrome.
Patel SS; Rybicki L; Pohlman B; Bolwell B; Gerds AT; Hamilton BK; Hanna R; Kalaycio M; Majhail NS; Sobecks R
Hematol Oncol Stem Cell Ther; 2020 Sep; 13(3):160-165. PubMed ID: 31628924
[TBL] [Abstract][Full Text] [Related]
20. [A comparison of toxicity and efficacy between busulfan plus fludarabine and busulfan plus cyclophosphamide for allogeneic hematopoietic stem cell transplantation in acute myeloid leukemia].
Liu H; Fan ZP; Jiang QL; Huang F; Zhou HS; Zhang X; Yu GP; Wu MQ; Sun J; Liu QF
Zhonghua Nei Ke Za Zhi; 2012 Nov; 51(11):880-4. PubMed ID: 23291027
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
